Kymera_Images_Patients_Hero

Explore Our Clinical Trials

Patient Resources
Powerful New Opportunities to Treat Disease

Kymera is at the forefront of a new technology called targeted protein degradation that offers us a new way to treat disease.

kymeratx_patients_powerful-new-opportunities
Kymera_Images_Patients_Carousel-Static_Patients

Targeted Protein Degrader Medicines Work with Your Cells to Fight Disease 

Targeted protein degradation (TPD) harnesses the natural process your cells use to keep themselves healthy by identifying and tagging misshapen or old proteins and directing them toward the cell’s built-in recycling system. Our medicines are designed to work with this system to selectively remove proteins that cause disease, with the goal of creating more effective medicines.

Learn How TPD is Revolutionizing Medicine

Kymera_Images_Patients_Full-Bleed

Clinical Trials

Clinical trials advance disease treatment by testing the safety and efficacy of the investigational medicines we are developing. Talk to your physician about whether a clinical trial or novel treatment is right for you and discover more about our ongoing trials below.

Learn More About Our Approach

The safety and efficacy of these investigational agents have not been established. These agents are not approved by any regulatory body for any indication. 

KT-474 (SAR444656) is an investigational degrader in development for the treatment of immunological and inflammatory diseases

The safety and efficacy of KT-474 (SAR444656) is currently being evaluated in double blind, placebo-controlled, randomized Phase 2 clinical trials in adult patients with moderate to severe Hidradenitis Suppurativa and Atopic Dermatitis.

OPEN
Phase
Phase 2
Conditions
Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)

KT-253 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies

This is an open-label Phase 1 first-in-human study of KT-253 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.

OPEN
Phase
Phase 1
Conditions
Acute Lymphocytic Leukemia, Advanced Solid Tumors, Lymphomas, Myeloid Malignancies

KT-333 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies

This is an open-label Phase 1 first-in-human study of KT-333 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.

OPEN
Phase
Phase 1
Conditions
Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), Non-Hodgkin Lymphoma (NHL), Peripheral T-Cell Lymphoma (PTCL), Solid Tumors

Kymera’s investigational drugs are currently at a stage in development where we are focused on enrolling patients in our clinical trials and continuing to learn more about our investigational drugs’ safety and efficacy. At this time, Kymera is not able to make expanded access available to its investigational drugs. For more information, please read our full expanded access policy.

Patient Advocacy

Kymera is proud to partner with advocacy groups that represent and support patients and their families living with a specific condition.

LLS_logo

As the leading source of free blood cancer information, education, and support for patients, survivors, families, and healthcare professionals, LLS helps patients navigate their cancer treatment and ensures they have access to quality, affordable, and coordinated care.